Remembering
Stanford L. Kurland
Stanford L. Kurland began his professional career in public accounting in 1975 at Grant Thorton, formerly known as Alexander Grant. One of his early assignments was at a mortgage bank called Countrywide Credit Industries and its operating subsidiary Countrywide Acceptance Company. Stan’s skills were quickly observed by Countrywide’s founders and he joined the organization in 1979. It didn’t take long for Stan to help Countrywide change the non-bank mortgage banking industry and over an almost 30-year career at Countrywide, he served as Chief Operating Officer, Chief Financial Officer, President and Director of the public company.
In 2008, Stan founded and led Pennymac Financial Services, Inc. and Pennymac Mortgage Investment Trust — now considered one of the premiere non-bank mortgage enterprises in America. At Pennymac, Stan was the Chairman and Chief Executive Officer of two NYSE-listed companies until his retirement at the end of 2019.
In early 2020, Stan was diagnosed with an inoperable brain tumor and began treatment at UCLA. Stan was fortunate to be in such good care until his passing in January 2021.
Despite the discomfort of radiation and chemotherapy, Stan was determined to help cure an “incurable” disease and lessen the distress of treatment for others. His work and legacy live on through this event that honors his memory and tireless philanthropy.
Please join us in this noble endeavor by giving directly to the UCLA Neuro-Oncology Program at giving.ucla.edu/StanfordKurland or by becoming a sponsor of this year’s Stanford L. Kurland Memorial Golf Classic benefiting the UCLA Neuro-Oncology Program.
Make a Donation Now Beome a Sponsor
You will be redirected to a UCLA page
UCLA Neuro-Oncology Program
The UCLA Neuro-Oncology program is dedicated to finding a cure for the most common, most invasive and most fatal type of malignant brian tumor: Glioblastoma (GBM). Timothy Cloughesy, M.D., Director of the UCLA Neuro-Oncology Program and Professor of Clinical Neurology, and David Nathanson, Ph.D., Associate Professor in the UCLA Ahmanson Translational Imaging Division in the Department of Molecular and Medical Pharmacology, lead the research and development effort that already has made a strong impact in battling the disease.
Thanks to the millions of dollars already raised by the Stanford L. Kurland Research Fund, UCLA Neuro-Oncology has made significant strides:
- Development of a promising medication designed to hinder tumor growth, which has been tested in clinical trial.
- Breakthrough discovery that Glioblastoma uniquely has two molecular blocks that thwart therapy. New treatment is now being tested to take down one of the blocks.
- An expanding team of experts that drive world-class drug discovery and research. Namely, renowned chemist, Dr. Alan Olivero has joined the team to lead drug discovery, bringing extensive pharmaceutical company experience.
- Groundbreaking “one-stop” research model that identifies the target, creates the drug, evaluates tumor response, and then quickly iterates – all onsite, for greater precision and efficiency. This tight research loop is conducted on multiple targets at the same time for exponential learning – and higher odds for effective outcomes.
- New equipment that enables onsite research, making funds go further and discovery move faster.
